Emerging drugs for the treatment of cervical cancer
2015
Introduction: Worldwide, most cervical cancer (CC) patients require the use of drug therapy either adjuvant, concurrent with radiation or palliative.Areas covered: This review briefly discusses the current achievements in treating CC with an emphasis in emerging agents.Expert opinion: Concurrent cisplatin with radiation and lately, gemcitabine-cisplatin chemoradiation has resulted in small but significant improvements in the treatment of locally advanced and high-risk early-stage patients. So far, only antiangiogenic therapy with bevacizumab added to cisplatin chemoradiation has demonstrated safety and encouraging results in a Phase II study. In advanced disease, cisplatin doublets yield median survival rates not exceeding 14 months. The first Phase III study of bevacizumab, added to standard chemotherapy cisplatin- or non-cisplatin-containing doublet, has shown significant increase in both overall survival and progression-free survival. Further studies are needed before bevacizumab plus chemotherapy can ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
129
References
17
Citations
NaN
KQI